Esophagitis is a major complication of chemoradiation therapy in patients with non-small cell lung cancer, producing significant morbidity and resulting in treatment interruptions. Amifostine at different doses and schedules has been found to reduce frequency or severity of esophagitis in this setting. In the Radiation Therapy Oncology Group 98-01 trial in non-small cell lung cancer patients receiving chemoradiation therapy, amifostine given intravenously four times weekly did not significantly reduce the frequency of grade 3 or 4 esophagitis; however, a significant reduction in severity over time was observed in patient swallowing diaries. The potential benefits of amifostine may have been obscured by inability to provide full amifostine doses due to toxicity associated with infusion, scheduling of doses, and inadequate follow-up to monitor severity of esophagitis over time. These issues are to be addressed in a randomized phase II trial of amifostine given subcutaneously or via intravenous bolus in non-small cell lung cancer patients undergoing chemoradiation treatment.

中文翻译：

---

氨磷汀在非小细胞肺癌化学放疗中的应用：评估皮下和静脉推注给药的II期试验的经验和设计。

食道炎是非小细胞肺癌患者化学放疗的主要并发症，其发病率很高，并导致治疗中断。已经发现，在这种情况下，不同剂量和时间表的氨磷汀可降低食道炎的发生频率或严重程度。在放射疗法肿瘤学小组98-01对接受化学放射疗法的非小细胞肺癌患者进行的试验中，每周四次静脉注射氨磷汀并没有显着降低3级或4级食管炎的发生率。然而，在患者吞咽日记中发现随着时间的推移严重程度会大大降低。由于与输注有关的毒性，剂量安排，随访不足，无法随时间监测食管炎的严重程度。这些问题将在接受化学放射治疗的非小细胞肺癌患者中通过皮下注射或静脉推注氨磷汀的II期随机试验解决。